Nextar Chempharma Solutions Ltd. is a clinical-stage pharmaceutical company dedicated to introducing innovative, safe and efficient drug products and drug delivery systems to improve the healthcare standards for millions of people worldwide. Nextar specialises in the chemical development of drug products and drug delivery systems (including nanotechnology-based products). The company is focusing on the development of a nano-scale liposomal drug delivery platform (BTLS), for treating brain-related and CNS diseases. The platform serves as a carrier for transporting drugs directly to the brain enabling penetration through the Blood Brain Barrier (BBB). Without a targeted drug-delivery system, most drugs are unable to reach and medicate the brain.
Nextar is certified to OECD-GLP, EU-cGMP, ISO 13485 and ISO 9001 and has been audited successfully by European notified bodies, US-FDA, the Israeli Ministry of Health, the Israeli Laboratory Accreditation Authority, and many others including Big Pharma.